Arecor Therapeutics PLC ARECOR STRENGTHENS COLLABORATION WITH PARTNER (7899P)
February 14 2023 - 2:15AM
UK Regulatory
TIDMAREC
RNS Number : 7899P
Arecor Therapeutics PLC
14 February 2023
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR STRENGTHENS COLLABORATION WITH TOP 5 GLOBAL
PHARMACEUTICAL PARTNER THROUGH ADDITIONAL FORMULATION AGREEMENT
- Eighth new technology partnership with major pharmaceutical and biotech companies since IPO
Cambridge, UK, 14 February 2023 : Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, today announces that it has signed an
additional formulation study agreement with its top five global
pharmaceutical partner, building on a collaboration formed in
2022.
Under the terms of this agreement, Arecor will use its
proprietary formulation technology platform, Arestat(TM), to
develop improved, stable, high concentration, liquid formulations
of its proprietary product. The partner company will fund the
initial development work and have the option to acquire the rights
to the new proprietary formulations and associated intellectual
property under a technology licensing model. This agreement follows
the first agreement with the partner company, announced in June
2022.
Sarah Howell, Chief Executive Officer of Arecor, said: "The
expansion of this important collaboration with a leading
pharmaceutical company clearly demonstrates Arecor's expertise and
the adaptability of our Arestat (TM) platform. This is the eighth
new technology partnership with major pharmaceutical and biotech
companies since Arecor's IPO in June 2021, which shows the need for
our technology among leading pharmaceutical companies developing
innovative products.
"This is key to the positive impact we can bring to our
partners' development programmes, not only providing upside
potential to Arecor from future licensing opportunities, but also
further cementing our reputation within the industry as the go-to
partner for challenging and complex formulation expertise."
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Lindsey Tel: +44 (0) 20 3709 5700
Neville Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat(TM) platform is supported by an extensive patent
portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRDGGDDXDBDGXX
(END) Dow Jones Newswires
February 14, 2023 02:15 ET (07:15 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jul 2023 to Jul 2024